Hostname: page-component-7479d7b7d-q6k6v Total loading time: 0 Render date: 2024-07-12T02:51:05.504Z Has data issue: false hasContentIssue false

New Potential Molecular Targets for Cannabis Addition

Published online by Cambridge University Press:  16 April 2020

M. Vieira-Coelho
Affiliation:
Institute of Pharmacology and Therapeutics, Faculty of Medicine, Porto University, Porto, Portugal Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal Department of Psychiatry, Hospital de S. João, Porto, Portugal
J. Azevedo
Affiliation:
Department of Psychiatry, Hospital de S. João, Porto, Portugal
M. Esteves
Affiliation:
Department of Psychiatry, Hospital de S. João, Porto, Portugal

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Cannabis is considerer the most widely abused illicit drug in the world. The recent rising prevalence of cannabis use by young adults and increasing evidence of adverse health effects makes the search for new pharmacotherapy to reduce cannabis abuse extremely important. To date no medication has been approved for the treatment of cannabis addition.

This study reviews recent results with potential interest for future pharmacological treatment of Cannabis dependence. Most of the relevant data obtained for treatment of cannabis dependence target the endocannabinoid or the central cholinergic systems, both involved and interact in brain systems implicated drug reinforcement. In laboratory animals blockade of cannabinoids CB1 receptors reverses central effects of cannabinoids. Rimonabant is a selective, orally active, cannabinoid CB1 receptor antagonist (inverse agonist) that has been shown in animals to modulate cannabinoid signaling in brain reward circuit. In humans, it has been shown that rimonabant, single or repeated oral doses blocked psychological and physiological effects of smoked marijuana (1). Although psychiatric adverse side affects like depression were reported with rimonabant, this compound was already been approved for treatment of obesity and metabolic syndrome. Very recently, blockade of α7 nicotinic receptors was shown to reverse abuse-related behavioral and neurochemical effects of cannabinoids in rats (2).

In conclusion, besides cannabinoid CB1 receptor, the homomeric α7 nicotinic receptors are novel molecular targets in the development of new drugs for treatment of cannabis addition.

Type
P01-82
Copyright
Copyright © European Psychiatric Association 2009

References

References:

Solinas, M., et al. J Neurosci 2007; 27(21): 56155620Google Scholar
Huestis, M.A., et al. Psychopharmacol 2007; 194(4): 505515CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.